Several oncogenic drivers have been linked to the development of prostate cancer, including I: Gene aberrations of cell‐signaling and genetic‐repairing genes (e.g., PI3K, BRCA, and PTEN, etc.); II: Androgen receptor gene amplification and overexpression in hormone‐refractory prostate cancer, as well as copy number variations of androgen receptor in CRPC; III: Relevant gene point mutations (e.g., F877L, TP53, and FOXA1, etc.); IV: Prostate cancer metastatic progression and germline variations. This evidence concerns the gene FOXA1 and prostate cancer.